Retatrutide, a novel dual agonist of the GLP-1 target and glucose-dependent secreted polypeptide (GIP) target, is exhibiting promising results in initial clinical trials . Ongoing examination suggests https://enrollbookmarks.com/story21303814/retatrutide-emerging-research-and-projected-therapeutic-applications